EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Development of a Non-Invasive Screening Method Based on Serum microRNAs to Quantify the Percentage of Liver Steatosis

Polina Soluyanova, Guillermo Quintás iD, Álvaro Pérez-Rubio iD, Iván Rienda iD, Erika Moro, Marcel van Herwijnen, Marcha Verheijen, Florian Caiment, Judith Pérez-Rojas iD, Ramón Trullenque-Juan, Eugenia Pareja, Ramiro Jover iD

Biomolecules · 2024

DOI: 10.3390/biom14111423 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Polina Soluyanova und 11 weiteren Autor:innen. Beteiligte Einrichtung: Unidad Mixta de Investigación en Hepatología Experimental, IIS Hospital La Fe, 46026 Valencia, Spain. Hauptthemen laut MEDLINE: MicroRNAs, Fatty Liver. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Commission under the Horizon 2020 Research and Innovation Framework program, Instituto de Salud Carlos III (ISCIII) co-funded by the European Union, MCIN/AEI/10.13039/501100011033 and "ERDF A way of making Europe" "European Union".

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) is often asymptomatic and underdiagnosed; consequently, there is a demand for simple, non-invasive diagnostic tools. In this study, we developed a method to quantify liver steatosis based on miRNAs, present in liver and serum, that correlate with liver fat. The miRNAs were analyzed by miRNAseq in liver samples from two cohorts of patients with a precise quantification of liver steatosis. Common miRNAs showing correlation with liver steatosis were validated by RT-qPCR in paired liver and serum samples. Multivariate models were built using partial least squares (PLS) regression to predict the percentage of liver steatosis from serum miRNA levels. Leave-one-out cross validation and external validation were used for model selection and to estimate predictive performance. The miRNAseq results disclosed (a) 144 miRNAs correlating with triglycerides in a set of liver biobank samples (n = 20); and (b) 124 and 102 miRNAs correlating with steatosis by biopsy digital image and MRI analyses, respectively, in liver samples from morbidly obese patients (n = 24). However, only 35 miRNAs were common in both sets of samples. RT-qPCR allowed to validate the correlation of 10 miRNAs in paired liver and serum samples. The development of PLS models to quantitatively predict steatosis demonstrated that the combination of serum miR-145-3p, 122-5p, 143-3p, 500a-5p, and 182-5p provided the lowest root mean square error of cross validation (RMSECV = 1.1, p-value = 0.005). External validation of this model with a cohort of mixed MASLD patients (n = 25) showed a root mean squared error of prediction (RMSEP) of 5.3. In conclusion, it is possible to predict the percentage of hepatic steatosis with a low error rate by quantifying the serum level of five miRNAs using a cost-effective and easy-to-implement RT-qPCR method.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsFatty LiverHumansFemaleMaleMiddle AgedAdultLiverBiomarkers

Stichwörter der Autor:innen

Metabolic dysfunction-associated steatotic liver diseaseliver steatosismicroRNApartial least squares regressionquantitative predictionserum biomarker

Substanzen

MicroRNAsBiomarkers

Autor:innen und Institutionen

  • Unidad Mixta de Investigación en Hepatología Experimental, IIS Hospital La Fe, 46026 Valencia, Spain.
  • Departamento de Bioquímica y Biología Molecular, Universidad de Valencia, 46010 Valencia, Spain.
  • Health and Biomedicine, LEITAT Technological Center, 08225 Terrassa, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), ISCIII, 28029 Madrid, Spain.
  • Servicio de Cirugía General y Aparato Digestivo, Hospital Universitario Dr. Peset, 46017 Valencia, Spain.
  • Pathology Department, Hospital Universitario y Politécnico La Fe, 46026 Valencia, Spain.

ORCID-Profile: Guillermo Quintás, Álvaro Pérez-Rubio, Iván Rienda, Judith Pérez-Rojas, Ramiro Jover

Förderung

  • European Commission under the Horizon 2020 Research and Innovation Framework program
  • Instituto de Salud Carlos III (ISCIII) co-funded by the European Union
  • MCIN/AEI/10.13039/501100011033 and "ERDF A way of making Europe" "European Union"
  • FUNSECO (Fundación de la Sociedad Española de Cirugía de la Obesidad)
  • European Commission under the Horizon2020 Research and Innovation Framework program
  • Instituto de Salud Carlos III (ISCIII)
  • European Union
  • MCIN/AEI/10.13039/501100011033

Zitieren

APA

Soluyanova, P., Quintás, G., Pérez-Rubio, Á., Rienda, I., Moro, E., van Herwijnen, M., Verheijen, M., Caiment, F., Pérez-Rojas, J., Trullenque-Juan, R., Pareja, E., & Jover, R. (2024). The Development of a Non-Invasive Screening Method Based on Serum microRNAs to Quantify the Percentage of Liver Steatosis. Biomolecules. https://doi.org/10.3390/biom14111423

Vancouver

Soluyanova P, Quintás G, Pérez-Rubio Á, Rienda I, Moro E, van Herwijnen M, et al. The Development of a Non-Invasive Screening Method Based on Serum microRNAs to Quantify the Percentage of Liver Steatosis. Biomolecules. 2024. doi:10.3390/biom14111423

BibTeX
@article{Soluyanova2024,
  author = {Soluyanova, Polina and Quintás, Guillermo and Pérez-Rubio, Álvaro and Rienda, Iván and Moro, Erika and van Herwijnen, Marcel and Verheijen, Marcha and Caiment, Florian and Pérez-Rojas, Judith and Trullenque-Juan, Ramón and Pareja, Eugenia and Jover, Ramiro},
  title = {The Development of a Non-Invasive Screening Method Based on Serum microRNAs to Quantify the Percentage of Liver Steatosis},
  journal = {Biomolecules},
  year = {2024},
  doi = {10.3390/biom14111423}
}
Kostenlos starten →